(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2014 (20.03.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/041195 A1

(51) International Patent Classification:
C07K 14/605 (2006.01) *A61K 38/26* (2006.01)

(21) International Application Number:
PCT/EP2013/069286

(22) International Filing Date:
17 September 2013 (17.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12184744.6 17 September 2012 (17.09.2012) EP
61/701,952 17 September 2012 (17.09.2012) US
61/784,294 14 March 2013 (14.03.2013) US

(71) Applicants: **ZEALAND PHARMA A/S** [DK/DK]; Smedeland 36, DK - 2600 Glostrup (DK). **BOEHRINGER INGELHEIM GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors: **TOLBORG, Jakob Lind**; Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup (DK). **FOSGERAU, Keld**; Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup (DK). **NØRREGARD, Pia**; Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup (DK). **JUST, Rasmus**; Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup (DK). **RIBER, Ditte**; Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup (DK). **HAMPRECHT, Dieter Wolfgang**; Boehringer Ingelheim International GmbH, Bingerstrasse 173, 55216 Ingelheim (DE). **AUGUSTIN, Robert**; Boehringer Ingelheim International GmbH, Bingerstrasse 173, 55216 Ingelheim (DE). **THOMAS, Leo**; Boehringer Ingelheim International GmbH, Bingerstrasse 173, 55216 Ingelheim (DE). **RIST, Wolfgang**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(74) Agents: **FORREST, Graham** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London Greater London EC2V 8AS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/041195 A1

(54) Title: GLUCAGON ANALOGUES

(57) Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.